Overview

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Status:
Recruiting
Trial end date:
2026-11-15
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Bevacizumab